XML 31 R23.htm IDEA: XBRL DOCUMENT
v3.25.3

Product Revenues, Accounts Receivable, and Reserves for Product Sales (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Product Revenues Accounts Receivable And Reserves For Product Sales [Abstract] |
Schedule of Disaggregation of Product Revenue by Major Source | The table reflects product revenue by major source for the following periods (in thousands):
|  |  |  |  |  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | Therapeutic Area |  | Key Indications |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Products: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
EMPAVELI |  | Rare Disease |  | PNH, C3G (1), IC-MPGN (1) |  | $ | 26,827 |  |  | $ | 24,611 |  |  | $ | 67,315 |  |  | $ | 74,733 |
SYFOVRE |  | Ophthalmology |  | GA |  |  | 150,928 |  |  |  | 151,960 |  |  |  | 431,727 |  |  |  | 444,049 |
Total Product revenue, net |  |  |  |  |  | $ | 177,755 |  |  | $ | 176,571 |  |  | $ | 499,042 |  |  | $ | 518,782 |
(1) The FDA approved EMPAVELI for the treatment of C3G and IC-MPGN on July 28, 2025.
Summary of Product Revenue Allowance and Reserve Categories | Th e following table summarizes activity in each of the product revenue allowance and reserve categories for the three and nine months ended September 30, 2025 (in thousands):
|  | Fees and patient assistance |  |  | Government and other rebates |  |  | Returns |  |  | Total |
Ending balance at December 31, 2024 |  | $ | 11,589 |  |  | $ | 31,533 |  |  | $ | 2,023 |  |  | $ | 45,145 |
Provision related to sales in the current period |  |  | 10,277 |  |  |  | 24,139 |  |  |  | 976 |  |  |  | 35,392 |
Adjustments related to prior period sales |  |  | 439 |  |  |  | (13 | ) |  |  | (382 | ) |  |  | 44 |
Credits and payments made |  |  | (13,084 | ) |  |  | (28,467 | ) |  |  | (126 | ) |  |  | (41,677 | )
Ending balance at March 31, 2025 |  | $ | 9,221 |  |  | $ | 27,192 |  |  | $ | 2,491 |  |  | $ | 38,904 |
Provision related to sales in the current period |  |  | 12,138 |  |  |  | 30,823 |  |  |  | 1,083 |  |  |  | 44,044 |
Adjustments related to prior period sales |  |  | (66 | ) |  |  | 185 |  |  |  | 852 |  |  |  | 971 |
Credits and payments made |  |  | (10,833 | ) |  |  | (27,623 | ) |  |  | (941 | ) |  |  | (39,397 | )
Ending balance at June 30, 2025 |  | $ | 10,460 |  |  | $ | 30,577 |  |  | $ | 3,485 |  |  | $ | 44,522 |
Provision related to sales in the current period |  |  | 12,695 |  |  |  | 38,426 |  |  |  | 1,152 |  |  |  | 52,273 |
Adjustments related to prior period sales |  |  | 366 |  |  |  | (12 | ) |  |  | (211 | ) |  |  | 143 |
Credits and payments made |  |  | (12,436 | ) |  |  | (34,730 | ) |  |  | (2,324 | ) |  |  | (49,490 | )
Ending balance at September 30, 2025 |  | $ | 11,085 |  |  | $ | 34,261 |  |  | $ | 2,102 |  |  | $ | 47,448 |
The following table summarizes activity in each of the product revenue allowance and reserve categories for the three and nine months ended September 30, 2024 (in thousands):
|  | Fees and patient assistance |  |  | Government and other rebates |  |  | Returns |  |  | Total |
Ending balance at December 31, 2023 |  | $ | 5,674 |  |  | $ | 8,898 |  |  | $ | 2,053 |  |  | $ | 16,625 |
Provision related to sales in the current period |  |  | 9,575 |  |  |  | 13,125 |  |  |  | 1,355 |  |  |  | 24,055 |
Adjustments related to prior period sales |  |  | 146 |  |  |  | (19 | ) |  |  | (96 | ) |  |  | 31 |
Credits and payments made |  |  | (9,724 | ) |  |  | (9,906 | ) |  |  | (1,859 | ) |  |  | (21,489 | )
Ending balance at March 31, 2024 |  | $ | 5,671 |  |  | $ | 12,098 |  |  | $ | 1,453 |  |  | $ | 19,222 |
Provision related to sales in the current period |  |  | 10,025 |  |  |  | 17,777 |  |  |  | 1,039 |  |  |  | 28,841 |
Adjustments related to prior period sales |  |  | (131 | ) |  |  | 354 |  |  |  | (983 | ) |  |  | (760 | )
Credits and payments made |  |  | (9,635 | ) |  |  | (14,640 | ) |  |  | (326 | ) |  |  | (24,601 | )
Ending balance at June 30, 2024 |  | $ | 5,930 |  |  | $ | 15,589 |  |  | $ | 1,183 |  |  | $ | 22,702 |
Provision related to sales in the current period |  |  | 11,455 |  |  |  | 25,364 |  |  |  | 1,380 |  |  |  | 38,199 |
Adjustments related to prior period sales |  |  | 2,332 |  |  |  | 420 |  |  |  | — |  |  |  | 2,752 |
Credits and payments made |  |  | (12,078 | ) |  |  | (17,695 | ) |  |  | (979 | ) |  |  | (30,752 | )
Ending balance at September 30, 2024 |  | $ | 7,639 |  |  | $ | 23,678 |  |  | $ | 1,584 |  |  | $ | 32,901 |
Schedule of Customer Accounted for 10% of More of Gross Product Revenues and Accounts Receivable | Significant customers - Gross product revenues and product sales receivable from the Company's customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total product sales receivable consisted of the following:
|  | Percent of Total Gross Product Revenues
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
Customer A |  | 13% |  | 12% |  | 12% |  | 13%
Customer C |  | 21% |  | 17% |  | 19% |  | 18%
Customer D |  | 58% |  | 61% |  | 59% |  | 59%
|  | Percent of Product Sales Receivable
|  | As of September 30,
|  | 2025 |  | 2024
Customer A |  | 4% |  | 3%
Customer C |  | 21% |  | 24%
Customer D |  | 67% |  | 61%
Schedule of Factoring of Accounts Receivable and Associated Fees | Factoring of accounts receivable and associated fees for the three and nine months ended September 30, 2025 and 2024 were as follows (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Accounts receivable sold |  | $ | — |  |  | $ | 56,590 |  |  | $ | 199,448 |  |  | $ | 56,590 |
Less: factoring fees |  |  | — |  |  |  | (672 | ) |  |  | (2,433 | ) |  |  | (672 | )
Net cash proceeds |  | $ | — |  |  | $ | 55,918 |  |  | $ | 197,015 |  |  | $ | 55,918 |

X
- Definition Product revenue reserves and allowances. + References No definition available. + Details
Name: | apls_ProductRevenueReservesAndAllowancesTableTextBlock
Namespace Prefix: | apls_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product revenues, accounts receivable, and reserves for product sales. + References No definition available. + Details
Name: | apls_ProductRevenuesAccountsReceivableAndReservesForProductSalesAbstract
Namespace Prefix: | apls_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details
Name: | us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration